The solar end game: bibliometric analysis, research and development evolution, and patent activity of hybrid photovoltaic/thermal-phase change material.

Solar photovoltaic-thermal hybrid with phase change material (PVT-PCM) emerges as an intelligent game changer to stimulate the clean, reliable, and affordable renewable energy technology. This PVT-PCM technology can be manipulated into generating both electricity and thermal energy that feature its practicality for residential and industrial applications. Hybridized of PCM into PVT design adds value to existing architecture with its capability to store excess heat that can be used during insufficient solar irradiation. Present work gives overview of the PVT-PCM system on technology innovation toward commercialization (viz, solar end game) subjected to bibliometric analysis, research and development evolution, and patent activity. A consolidation of these review articles was decluttered to focus on the performance and efficiency of PVT-PCM technology based on the fact that commercialization is ready once the technology is completed and qualified (at technology readiness level, TRL: 8). Economic review was conducted to understand the feasibility of the existing solar technologies and how it affects the PVT-PCM market price. Based on the contemporary findings, promising performance of PVT-PCM technology has underpinned its feasibility and technology readiness. China has predominant local and international framework and expected to be the PVT-PCM technology trendsetter in the next years through its strong international collaborative projects and pioneer in PVT-PCM patent filing. This present work underscores the solar end-game strategy and recommendation to create a path forward to achieve clean energy transition. Though, as to the date of submission of this article, no industry  has found to manufacture/sell this hybrid technology in the market.

The efficacy of anakinra compared to standard care of treatment for COVID-19: a meta-analysis.

BACKGROUND: As SARS-CoV-2 continues to spread worldwide, this study brings to light the link that anakinra, a recombinant IL-1 receptor antagonist, has in averting grave clinical outcomes. The objectives of this meta-analysis are to investigate the effects of anakinra in interventional groups compared to control/standard of care groups on mortality along with the provision of a prevalence estimate of the variables associated with death (C-reactive protein-CRP, ferritin, acute respiratory distress syndrome-ARDS). METHODS: According to the PRISMA 2020 statement guidelines, a systematic search was conducted from December 19, 2020, until December 10, 2021, with keywords including COVID-19, coronavirus, SARS-CoV-2, anakinra, mortality, across the following databases: PubMed/MEDLINE, Scopus, Web of Science, CINAHL Plus, and Cochrane. A random-effects model was applied using RevMan 5.4 for all statistical analyses. RESULTS: The meta-analysis pooled in 1297 participants with 565 (43.6%) patients in the anakinra group. When comparing to the control/standard of care group, the anakinra group had a much lower risk of death (RR = 0.47. 95% CI = 0.37-0.59, Z = 6.44; P < 0.001). In addition to the risk of death being reduced by around 50% in the interventional group, prognostic indicators such as CRP and ferritin were improved with fewer occurrences of severe ARDS. DISCUSSION: Patients with COVID-19 pneumonia may be treated with anakinra as a safe and viable treatment modality to defer adverse outcomes such as a death in the 28-day period. Despite an auspicious premise, our findings must be used with caution as adequately powered randomized, placebo-controlled trials are required to corroborate these findings.

Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.

BACKGROUND: The approval of anti-PD-L1 drugs, including atezolizumab/pembrolizumab in triple-negative breast cancer (TNBC), potentially improveme treatment regimens available for TNBC. METHODS: We conducted a meta-analysis to review the efficacy of atezolizumab/pembrolizumab for the treatment of TNBC in both the adjuvant and neoadjuvant settings. We calculated standardized mean difference (SMD) for the associations of progression-free survival (PFS) and overall survival (OS) and odds ratios (ORs) to estimate objective response rate (ORR) and pathological complete response (pCR), using 95% confidence intervals (CIs). RESULTS: Six clinical trials comprising 3612 patients were included. For adjuvant therapies, the ORR (OR = 1.26, P = 0.04) of atezolizumab/pembrolizumab plus chemotherapy was higher in the intention to treat (ITT) arms than the placebo groups in TNBC. A positive effect size was found for PFS in the ITT arms (d = 1.55, P < 0.001). The atezolizumab plus chemotherapy group had a positive effect size for OS compared to control groups (d = 0.52, P < 0.001). In the neoadjuvant setting, patients in ITT arms had higher pCR rates than the control groups (OR = 1.61, P = 0.001). CONCLUSION: We collate evidence of atezolizumab/pembrolizumab as viable therapeutics among patients with TNBC with PD-L1 subgroups deriving higher benefits.

PLAIN LANGUAGE SUMMARYImmune checkpoint inhibitors (ICI), atezolizumab and pembrolizumab, have received approval for patients with triple-negative breast cancer (TNBC) expressing PD-L1. Thus far, it has only been approved for patients with unresectable locally advanced or metastatic TNBC. With the IMpassion 130 and KEYNOTE-355 trials introducing the immunotherapy era for TNBC, ongoing trials have started exploring the outcomes of the ICIs in early-stage TNBC in combination. Recently, the ICIs have demonstrated positive efficacy outcomes in neoadjuvant settings. Both the ICIs have shown a safe profile in terms of adverse events. The recent advances made by clinical trials indicate promising results for early-stage and advanced/metastatic TNBC. However, there is a need to harmonize and explore biomarkers and endpoints in the ongoing clinical trials to enhance patient treatment protocols. As TNBC is an aggressive subtype, exploring beyond the PD-L1 positive subgroup is necessary to expand the target population receiving ICIs for TNBC.